|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When mice bearing s.c. MG-63 OS xenografts were intratumorally injected with Ad-sCE2 and CPT-11, this resulted in a significant difference in time to reach 2000 mm(3) in tumor volume as compared with animals receiving Ad-sCE2 or CPT-11 treatment (P < 0.05).
|
12939466 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High CES2 expression in tumor tissue was associated with longer overall survival in resectable and borderline resectable patients who underwent neoadjuvant FOLFIRINOX treatment (hazard ratio = 0.14, 95% confidence interval = 0.04 to 0.51, P = .02).
|
26025324 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Neither TOPO-1 nor CES-2 had significant correlation with age, gender, tumor site, tumor grade and metastatic sites in mCRC patients.
|
29261002 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Oral treatment of xenograft models with 3.2 mg/kg LY2334737 once a day for 21 days showed greater tumor growth inhibition of CES2 transfectant than the mock transfectant (P ≤ 0.001).
|
23325581 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that the CES2Delta(458-473) transcript accounts for an average of 6% of total CES2 transcripts in colon tissue, and there is large interindividual variation in CES2 expression in both tumor and normal colon samples.
|
17636009 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Thus, tissue adjacent to the tumor was a substantial source of CES-2 with high expression in plasma cells.
|
27149931 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Hepatic CES-2 mediated activation of irinotecan clearly correlated with tumour replacement by fibrosis (r (2) = 0.54, p = 0.01).
|
23756919 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A number of the predicted therapies were found to be active against the tumors in particular BGJ398 (FGFR2) and ICE-T. Re-transplanted ICE-T treated tumorgrafts demonstrated a decreased response to ICE-T recapitulating the patient's refractory disease.
|
24687871 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results showed that the expression of CES2, UGTA1A1, and GUSB varies in colorectal pathology tissues and that the expression of CES2 is somewhat related to tumor staging.
|
24195516 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No significant relationship was found between CES2 830C>G genotype and the toxicity and therapeutic efficacy (tumour response, event-free survival) of irinotecan in colorectal cancer patients.
|
17483951 |
2008 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In this study, we examined the relationship between <i>TP53</i> gene status and CES2 expression in human colorectal cancer.
|
29651325 |
2018 |
|
Colorectal Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CES-2 expression was analyzed by immunohistochemistry in colorectal cancer (CRC) compared to colonic inflammation as well as in liver and peripheral blood.
|
27149931 |
2016 |
|
Colorectal Carcinoma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
The methylation of the CES2 gene is irrelevant to the morbidity associated with colorectal cancer.
|
24195516 |
2014 |
|
Diarrhea
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
The presence of two polymorphisms (CDD 943insC and CES 2 Exon3 6046 G/A) were associated with a non-statistically significant higher incidence of grade 3 hand-foot syndrome (HFS) (p=0.07) and grade 3-4 diarrhoea (p=0.09), respectively.
|
18473752 |
2008 |
|
Diarrhea
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Co-administration with CES2 inhibitors may ameliorate CPT-11 associated lifethreatening diarrhea or improve the half-lives of CES2-substrate drugs.
|
29210644 |
2018 |
|
Diarrhea
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In summary, glabridin was a potent and specific inhibitor targeting intracellular CES2A, which could be used as an ideal lead compound to develop more efficacious CES2A inhibitors for modulating the pharmacokinetic behaviors of CES2A-substrate drugs and alleviating irinotecan-induced diarrhea.
|
31260759 |
2019 |
|
Neuroblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
IL-1beta and ICE mRNA are not altered upon beta-amyloid(25-35) induced neurotoxicity in human neuroblastoma cells.
|
10715578 |
2000 |
|
Neuroblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
CES2 RNA expression was observed in neuroblastoma cells, and its expression in neuroblastoma cell lines was positively correlated with sensitivity to CPT-11 and apoptosis after CPT-11 exposure in vitro.
|
23480903 |
2013 |
|
Neuroblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
ICE may play an important role in regulating the apoptotic process of neuroblastoma.
|
9516857 |
1997 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Ibrutinib in combination with R-ICE demonstrates tolerability and efficacy in rel/ref DLBCL, particularly of non-GC phenotype.
|
29386196 |
2018 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
|
22408263 |
2012 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
|
28143954 |
2017 |
|
Pancreatic carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that CES2 expression and activity, by mediating the intratumoral activation of irinotecan, is a contributor to FOLFIRINOX sensitivity in pancreatic cancer and CES2 assessment may define a subset of patients likely to respond to irinotecan based therapy.
|
26025324 |
2015 |
|
Pancreatic carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Measuring human carboxylesterase 2 activity in pancreatic cancer patient-derived xenografts using a ratiometric fluorescent chemosensor.
|
31803422 |
2019 |
|
Pancreatic carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The strong associations between low MAP4K5 expression and loss of E-cadherin, reduced CES2 expression and decreased overall survival may suggest an important role of MAP4K5 in epithelial-to-mesenchymal transition, chemotherapy resistance and tumor progression in pancreatic cancer.
|
27023625 |
2016 |